INHIBIKASE THERAPEUTICS INC (IKT)
Health Care · Clinical-stage biopharmaceuticals / pulmonary hypertension therapeutics · NASDAQ
A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no approved products or operating revenue.
What INHIBIKASE THERAPEUTICS INC does
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company focused on the development of IKT-001, a novel therapeutic candidate for treating pulmonary arterial hypertension (PAH). The company is currently conducting Phase 3 clinical trials (the IMPRES study) to support regulatory approval and potential commercialization of IKT-001. With no approved products, no commercial revenue, and limited operating history, Inhibikase is entirely dependent on raising capital to fund its drug development activities and the completion of clinical trials.
Themes: PAH / pulmonary arterial hypertension, clinical-stage drug development, cardiovascular therapeutics
Fundamentals
- Price$2.50 as of 2026-08-24 close
- Market cap$349M as of 2026-08-24
- 1-year return+32.3% 2025-08-22 close $1.89 → 2026-08-24 close $2.50
- P/En/a negative earnings
- Net margin-5981.3% as of 2026-08-24
- ROE-57.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.38 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How IKT compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How INHIBIKASE THERAPEUTICS INC looks technically
INHIBIKASE THERAPEUTICS INC (IKT) is trading 36.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 121 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative). It just made a new 20-day high, pushing above its recent trading range. It is 1.6% below its 52-week high (its highest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 36.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +36.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.15 | $2.15 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.83 | $1.83 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 2.525. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 121 trading days ago — a "golden cross", a bullish long-term signal | 121 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control | 38.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($2.31 to $2.54) — its "stochastic" reading is 83 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 82.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.54 | $2.54 |
|---|---|---|
| From the 52-week high | it is 1.6% below its 52-week high (its highest price of the past year) | -1.6% |
| Above the 52-week low | it is 88.0% above its 52-week low (its lowest price of the past year) | +88.0% |
| Below the 52-week high | it is 1.6% below its highest point of the past year | 1.6% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $70.80 (set on 2020-12-23) | $70.80 |
| Given back of the 52-week move | over the past year its closes ranged ($1.41 to $2.50), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.79 to $1.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 96.5% below its all-time high | -96.5% |
| Nearest price level | it is trading 1.4% below a resistance level at $2.54 — a price it turned at three times since 2025-01-16, most recently on 2026-08-10. Since 2024-08-26 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $0.79 (set on 2023-10-10) | $0.79 |
| Above the all-time low | it is 216.5% above its all-time low | +216.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1263 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1263 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.20 and $2.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.20 – $2.38 – $2.55 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 5.3 daily ranges above its 200-day average price (36.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.91× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 45 sessions ago and has not traded back through the level it left behind at 1.68 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.9% gap down opened on 2026-08-12 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 8 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +6.38% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.0 percentage points (the stock gained 7.3% while the market gained 3.3%) | +4.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 45.5 percentage points (the stock gained 47.9% while the market gained 2.4%) | +45.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 10.9 percentage points (the stock gained 22.0% while the market gained 11.1%) | +10.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 14.0 percentage points (the stock gained 32.3% while the market gained 18.3%) | +14.0% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.8% of the share price. | +21.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.87 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +33.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $2.42 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +3.2% |
Price levels it has turned at before
IKT last closed at $2.50 on 2026-08-24. Since 2024-08-26 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.54 | Resistance | 1.4% above the last close | turned there three times · 2025-01-16 to 2026-08-10 |
| $2.36 | Support | 5.5% below the last close | turned there twice · 2025-05-02 to 2026-07-14 |
| $2.27 | Support | 9.4% below the last close | turned there twice · 2025-05-14 to 2026-02-25 |
| $2.21 | Support | 11.6% below the last close | turned there twice · 2025-02-13 to 2025-04-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $2.52.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 6 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.11 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$6.00 range $3.00 – $8.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IKT
- Consensus EPS estimate-$0.09333 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products, no revenue, and dependence on successful completion of Phase 3 trials; failure to demonstrate efficacy or safety in the IMPRES study could prevent regulatory approval and destroy company viability","Substantial capital requirements to complete Phase 3 development and potential commercialization; inability to raise additional funding on acceptable terms could halt clinical trials and threaten long-term viability","Regulatory approval is uncertain and time-consuming; the FDA may reject the application, request additional studies, or impose unfavorable conditions that could delay or prevent commercialization of IKT-001"]
What changed in the latest 10-Q
AI-assisted comparison of IKT's 10-Q filed 2026-05-12 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- April 2026 announcement of first patient enrollment in IMPROVE-PAH Phase 3 study (NCT07365332)
- Description of FAST-EU initiative (Facilitating and Accelerating Strategic Trials in the European Union) commenced January 30, 2026
- European Medicines Agency determination permitting initiation in 12 European countries for total of 16 countries approved globally
- April 2026 Orphan Drug Designation application submission to FDA for IKT-001 for PAH
- Annual Report on Form 10-K for year ended December 31, 2025 filed March 26, 2026
- Company described as pursuing regulatory approvals in more than 25 countries globally
- Site activations expected to commence gradually during remainder of 2026
- Removed:
- Reference to discontinued risvodetinib (IKT-148009) program
- Discussion of medicinal chemistry program development of IKT-001
- Details of '501 trial' dose finding/dose equivalence study completed in 2023
- Bioequivalence establishment details (300 mg IKT-001 to 230 mg imatinib; 500 mg IKT-001 to 383 mg imatinib)
- January 19, 2024 FDA pre-NDA meeting details with Hematological Malignancy Review Team
- Discussion of global PAH market size ($7.66 billion in 2023) and growth rate (3.3%)
- Sotatercept (WINREVAIR) approval details and sales information ($1.4 billion annualized)
- Discussion of first imatinib reports in PAH (2005-2006) and Phase 2/3 IMPRES trial
- hERG ion channel study and IND filing details (August 9, 2024; cleared September 9, 2024)
- October 21, 2024 private placement closing mentioned (text truncated)
- Reworded:
- From 'developing therapeutics to modify the course of cardiopulmonary diseases' to 'developing IKT-001 for Pulmonary Arterial Hypertension'
- From 'forthcoming Phase 2b study' to 'Phase 3 clinical study, named IMPROVE-PAH, which is a single pivotal global study'
- From 'we have completed non-human primate safety studies' to 'We have completed a non-human primate safety study'
- From 'bioequivalence clinical trial in healthy volunteers' to 'bioequivalence clinical study in healthy volunteers'
- Annual Report reference changed from December 31, 2024 to December 31, 2025
- Notes:
- Older filing text appears truncated at end ('October 21, 2024, we closed a private placement with gross proceeds of approximately $110 million, before d'), limiting full comparison of sections beyond truncation point
- Newer filing also appears truncated at very end ('that product can'), limiting full comparison of final section
Risk Factors
- Added:
- Added bullet point about ability to deliver anti-remodeling, exercise capacity improvements, blood pressure or blood flow resistance improvements, or disease reversal benefits to patients with PAH (filed 2026-05-12)
- Added bullet point about potential for warrant holders to exercise warrants in accordance with their terms (filed 2026-05-12)
- Removed:
- Removed statement about ability to initiate and successfully enroll a Phase 2b trial or other clinical studies in pulmonary arterial hypertension (filed 2025-11-14)
- Removed statement about ability to initiate Phase 3 trials in pulmonary arterial hypertension (filed 2025-11-14)
- Removed statement about ability to successfully enroll or complete 'any clinical trial' (filed 2025-11-14)
- Removed reference to 'securing requisite regulatory approvals' from first product development bullet (filed 2025-11-14)
- Removed 'Deferred offering costs' line item from balance sheet (filed 2025-11-14)
- Removed 'Equipment and improvements, net' line item from balance sheet (filed 2025-11-14)
- Removed 'Right-of-use asset' line item from balance sheet (filed 2025-11-14)
- Removed 'Lease obligation, current' line item from balance sheet (filed 2025-11-14)
- Removed 'Contingent consideration liability' line item from balance sheet (filed 2025-11-14)
- Reworded:
- Changed 'our ability to obtain funding' to 'our ability to obtain sufficient or timely funding' in forward-looking statements (filed 2026-05-12)
- Changed 'our ability to conduct and complete Phase 3 studies of IKT-001 in pulmonary arterial hypertension to support regulatory approval and commercialization' replacing earlier phrasing about initiating Phase 3 trials (filed 2026-05-12)
- Changed 'our ability to successfully and timely enroll or complete clinical trials' replacing 'our ability to successfully enroll or complete any clinical trial' (filed 2026-05-12)
- Changed grammar in trademark section from 'are not incorporated' to 'is not incorporated' (filed 2026-05-12)
- Updated balance sheet dates from September 30, 2025/December 31, 2024 to March 31, 2026/December 31, 2025 (filed 2026-05-12)
- Notes:
- The older filing's financial data appears truncated or incomplete in the provided text
- Substantive changes in forward-looking statements relate to clinical development program progression and warrant matters
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for IKT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IKT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,180,297
- Reported value $15,422,900
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IKT had 19,135,668 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IKT had 13.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 21.49 days to cover at the same settlement.
- Reported short interest (shares) 19,135,668
- Short interest (% of shares outstanding) 13.7%
- Prior settlement (shares) 18,261,416
- Reported change 4.79%
- Days to cover (reported) 21.49
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Actelion (acquired by Johnson & Johnson)
- Gilead Sciences (PAH portfolio)
- United Therapeutics
- Reata Pharmaceuticals
- Gossamer Bio
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IKT vs…
INHIBIKASE THERAPEUTICS INC is found in…
Frequently asked questions
What does INHIBIKASE THERAPEUTICS INC (IKT) do?
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company focused on the development of IKT-001, a novel therapeutic candidate for treating pulmonary arterial hypertension (PAH). The company is currently conducting Phase 3 clinical trials (the IMPRES study) to support regulatory approval and potential commercialization of IKT-001.
What sector is INHIBIKASE THERAPEUTICS INC (IKT) in?
INHIBIKASE THERAPEUTICS INC (IKT) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceuticals / pulmonary hypertension therapeutics. It trades on NASDAQ.
Who are INHIBIKASE THERAPEUTICS INC's (IKT) competitors?
Notable peers of INHIBIKASE THERAPEUTICS INC (IKT) include Actelion (acquired by Johnson & Johnson), Gilead Sciences (PAH portfolio), United Therapeutics, Reata Pharmaceuticals and Gossamer Bio. This peer set is informational only — not financial advice.
Is INHIBIKASE THERAPEUTICS INC (IKT) overbought or oversold right now?
INHIBIKASE THERAPEUTICS INC (IKT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IKT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.